-+ 0.00%
-+ 0.00%
-+ 0.00%

Actinium To Present Abstracts On ATNM-400 And Actimab-A Programs Across Solid Tumors And Hematologic Oncology Applications At AACR Annual Meeting 2026

Benzinga·02/17/2026 12:46:43
Listen to the news

AACR Presentations to Feature ATNM-400 and Actimab-A Programs Across Solid Tumors and Hematologic Oncology Applications

NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of differentiated targeted radiotherapies, today announced that it will present two abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22, 2026 in San Diego, California.